{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,8,8]],"date-time":"2024-08-08T00:06:45Z","timestamp":1723075605434},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,6,15]],"date-time":"2020-06-15T00:00:00Z","timestamp":1592179200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,6,15]],"date-time":"2020-06-15T00:00:00Z","timestamp":1592179200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurooncol"],"published-print":{"date-parts":[[2020,8]]},"DOI":"10.1007\/s11060-020-03485-w","type":"journal-article","created":{"date-parts":[[2020,6,17]],"date-time":"2020-06-17T16:08:17Z","timestamp":1592410097000},"page":"27-33","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Melanoma brain metastases: is it time to eliminate radiotherapy?"],"prefix":"10.1007","volume":"149","author":[{"given":"Richard J.","family":"White","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen","family":"Abel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zachary D.","family":"Horne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Howard","family":"Edington","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Larisa","family":"Greenberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hashem","family":"Younes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christie","family":"Hilton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rodney E.","family":"Wegner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,6,15]]},"reference":[{"key":"3485_CR1","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.1016\/S0140-6736(04)16250-8","volume":"363","author":"DW Andrews","year":"2004","unstructured":"Andrews DW, Scott CB, Sperduto PW et al (2004) Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial. Lancet 363:1665\u20131672","journal-title":"Lancet"},{"key":"3485_CR2","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1056\/NEJMoa1805453","volume":"379","author":"HA Tawbi","year":"2018","unstructured":"Tawbi HA, Forsyth PA, Algazi A et al (2018) Combined nivolumab and ipilimumab in melanoma metastatic to the brain. N Engl J Med 379:722\u2013730","journal-title":"N Engl J Med"},{"key":"3485_CR3","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1016\/S1470-2045(18)30139-6","volume":"19","author":"GV Long","year":"2018","unstructured":"Long GV, Atkinson V, Lo S et al (2018) Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study. Lancet Oncol 19:672\u2013681","journal-title":"Lancet Oncol"},{"key":"3485_CR4","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/NEJMoa1003466","volume":"363","author":"FS Hodi","year":"2010","unstructured":"Hodi FS, O'Day SJ, McDermott DF et al (2010) Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363:711\u2013723","journal-title":"N Engl J Med"},{"key":"3485_CR5","doi-asserted-by":"publisher","first-page":"2006","DOI":"10.1056\/NEJMoa1414428","volume":"372","author":"MA Postow","year":"2015","unstructured":"Postow MA, Chesney J, Pavlick AC et al (2015) Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med 372:2006\u20132017","journal-title":"N Engl J Med"},{"key":"3485_CR6","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1016\/0895-4356(92)90133-8","volume":"45","author":"RA Deyo","year":"1992","unstructured":"Deyo RA, Cherkin DC, Ciol MA (1992) Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 45:613\u2013619","journal-title":"J Clin Epidemiol"},{"key":"3485_CR7","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1200\/JCO.2017.75.6536","volume":"36","author":"WA Stokes","year":"2018","unstructured":"Stokes WA, Bronsert MR, Meguid RA et al (2018) Post-treatment mortality after surgery and stereotactic body radiotherapy for early-stage non-small-cell lung cancer. J Clin Oncol 36:642\u2013651","journal-title":"J Clin Oncol"},{"key":"3485_CR8","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.2517-6161.1972.tb00899.x","volume":"34","author":"DR Cox","year":"1972","unstructured":"Cox DR (1972) Regression models and life- tables. J R Stat Soc 34:187\u2013220","journal-title":"J R Stat Soc"},{"key":"3485_CR9","doi-asserted-by":"publisher","first-page":"2265","DOI":"10.1002\/(SICI)1097-0258(19981015)17:19<2265::AID-SIM918>3.0.CO;2-B","volume":"17","author":"RB D'Agostino Jr","year":"1998","unstructured":"D'Agostino RB Jr (1998) Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med 17:2265\u20132281","journal-title":"Stat Med"},{"key":"3485_CR10","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","volume":"53","author":"ELKP Meier","year":"1958","unstructured":"Meier ELKP (1958) Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457\u2013481","journal-title":"J Am Stat Assoc"},{"key":"3485_CR11","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1016\/0360-3016(82)90060-8","volume":"8","author":"LL Doss","year":"1982","unstructured":"Doss LL, Memula N (1982) The radioresponsiveness of melanoma. Int J Radiat Oncol Biol Phys 8:1131\u20131134","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"3485_CR12","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.critrevonc.2016.12.003","volume":"110","author":"S Espenel","year":"2017","unstructured":"Espenel S, Vallard A, Rancoule C et al (2017) Melanoma: last call for radiotherapy. Crit Rev Oncol Hematol 110:13\u201319","journal-title":"Crit Rev Oncol Hematol"},{"key":"3485_CR13","doi-asserted-by":"publisher","first-page":"1699","DOI":"10.1016\/0360-3016(85)90223-8","volume":"11","author":"B Fertil","year":"1985","unstructured":"Fertil B, Malaise EP (1985) Intrinsic radiosensitivity of human cell lines is correlated with radioresponsiveness of human tumors: analysis of 101 published survival curves. Int J Radiat Oncol Biol Phys 11:1699\u20131707","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"3485_CR14","doi-asserted-by":"publisher","first-page":"e1440168","DOI":"10.1080\/2162402X.2018.1440168","volume":"7","author":"O Mohamad","year":"2018","unstructured":"Mohamad O, de Leon AD, Schroeder S et al (2018) Safety and efficacy of concurrent immune checkpoint inhibitors and hypofractionated body radiotherapy. Oncoimmunology. 7:e1440168","journal-title":"Oncoimmunology."},{"key":"3485_CR15","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1186\/1748-717X-9-143","volume":"9","author":"MA Dyer","year":"2014","unstructured":"Dyer MA, Arvold ND, Chen YH et al (2014) The role of whole brain radiation therapy in the management of melanoma brain metastases. Radiat Oncol 9:143","journal-title":"Radiat Oncol"},{"key":"3485_CR16","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1200\/JCO.2010.30.1655","volume":"29","author":"M Kocher","year":"2011","unstructured":"Kocher M, Soffietti R, Abacioglu U et al (2011) Adjuvant whole-brain radiotherapy versus observation after radiosurgery or surgical resection of one to three cerebral metastases: results of the EORTC 22952\u201326001 study. J Clin Oncol 29:134\u2013141","journal-title":"J Clin Oncol"},{"key":"3485_CR17","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1186\/s12885-017-3494-z","volume":"17","author":"JD Zindler","year":"2017","unstructured":"Zindler JD, Bruynzeel AME, Eekers DBP, Hurkmans CW, Swinnen A, Lambin P (2017) Whole brain radiotherapy versus stereotactic radiosurgery for 4\u201310 brain metastases: a phase III randomised multicentre trial. BMC Cancer 17:500","journal-title":"BMC Cancer"},{"key":"3485_CR18","unstructured":"Stereotactic Radiosurgery Compared with hippocampal-avoidant whole brain radiotherapy (HA-WBRT) plus memantine for 5\u201315 brain metastases. https:\/\/ClinicalTrials.gov\/show\/NCT03550391. Accessed 11 Oct 2019"},{"key":"3485_CR19","first-page":"CD009454","volume":"2014","author":"YY Soon","year":"2014","unstructured":"Soon YY, Tham IW, Lim KH, Koh WY, Lu JJ (2014) Surgery or radiosurgery plus whole brain radiotherapy versus surgery or radiosurgery alone for brain metastases. Cochrane Database Syst Rev 2014:CD009454","journal-title":"Cochrane Database Syst Rev"},{"key":"3485_CR20","doi-asserted-by":"publisher","first-page":"3132","DOI":"10.1200\/JCO.19.01414","volume":"37","author":"AM Hong","year":"2019","unstructured":"Hong AM, Fogarty GB, Dolven-Jacobsen K et al (2019) Adjuvant whole-brain radiation therapy compared with observation after local treatment of melanoma brain metastases: a multicenter, randomized phase III trial. J Clin Oncol 37:3132\u20133141","journal-title":"J Clin Oncol"},{"key":"3485_CR21","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1016\/S1470-2045(16)30053-5","volume":"17","author":"SB Goldberg","year":"2016","unstructured":"Goldberg SB, Gettinger SN, Mahajan A et al (2016) Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial. Lancet Oncol 17:976\u2013983","journal-title":"Lancet Oncol"},{"key":"3485_CR22","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/S1470-2045(12)70090-6","volume":"13","author":"K Margolin","year":"2012","unstructured":"Margolin K, Ernstoff MS, Hamid O et al (2012) Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial. Lancet Oncol 13:459\u2013465","journal-title":"Lancet Oncol"},{"key":"3485_CR23","first-page":"402","volume":"6","author":"CM Lanier","year":"2019","unstructured":"Lanier CM, Hughes R, Ahmed T et al (2019) Immunotherapy is associated with improved survival and decreased neurologic death after SRS for brain metastases from lung and melanoma primaries. Neurooncol Pract 6:402\u2013409","journal-title":"Neurooncol Pract"},{"key":"3485_CR24","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1186\/s40425-019-0588-y","volume":"7","author":"G Minniti","year":"2019","unstructured":"Minniti G, Anzellini D, Reverberi C et al (2019) Stereotactic radiosurgery combined with nivolumab or Ipilimumab for patients with melanoma brain metastases: evaluation of brain control and toxicity. J Immunother Cancer 7:102","journal-title":"J Immunother Cancer"},{"key":"3485_CR25","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/j.radonc.2018.06.017","volume":"128","author":"P Gabani","year":"2018","unstructured":"Gabani P, Fischer-Valuck BW, Johanns TM et al (2018) Stereotactic radiosurgery and immunotherapy in melanoma brain metastases: patterns of care and treatment outcomes. Radiother Oncol 128:266\u2013273","journal-title":"Radiother Oncol"}],"container-title":["Journal of Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-020-03485-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11060-020-03485-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-020-03485-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,7]],"date-time":"2024-08-07T20:51:44Z","timestamp":1723063904000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11060-020-03485-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,15]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,8]]}},"alternative-id":["3485"],"URL":"https:\/\/doi.org\/10.1007\/s11060-020-03485-w","relation":{},"ISSN":["0167-594X","1573-7373"],"issn-type":[{"type":"print","value":"0167-594X"},{"type":"electronic","value":"1573-7373"}],"subject":[],"published":{"date-parts":[[2020,6,15]]},"assertion":[{"value":"17 February 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 April 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 June 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"All authors involved have nothing to disclose and no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}